|
WO1992015579A1
(en)
|
1991-03-08 |
1992-09-17 |
Rhone-Poulenc Rorer International (Holdings) Inc. |
Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors
|
|
DE19833786A1
(de)
|
1998-07-18 |
2000-01-20 |
Schering Ag |
Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
|
|
ES2236056T3
(es)
|
2001-01-24 |
2005-07-16 |
Chiesi Farmaceutici S.P.A. |
Derivados de 2h-1-benzopirano, procedimientos para su preparacion y composiciones farmaceuticas de los mismos.
|
|
EP1417169A2
(en)
|
2001-08-11 |
2004-05-12 |
Bristol-Myers Squibb Pharma Company |
Selective estrogen receptor modulators
|
|
ATE481397T1
(de)
|
2002-04-24 |
2010-10-15 |
Merck Sharp & Dohme |
Modulatoren des östrogenrezeptors
|
|
CA2512000C
(en)
|
2002-12-26 |
2011-08-09 |
Eisai Co., Ltd. |
Selective estrogen receptor modulator
|
|
ES2573845T3
(es)
|
2004-06-25 |
2016-06-10 |
Janssen Pharmaceutica Nv |
Antagonistas de CCR2 de sales cuaternarias
|
|
CA2611712C
(en)
|
2005-06-14 |
2014-05-13 |
Baylor University |
Combretastatin analogs with tubulin binding activity
|
|
US8127618B1
(en)
|
2007-05-18 |
2012-03-06 |
Pacesetter, Inc. |
Implantable micro-electromechanical system sensor
|
|
EP2048126A1
(de)
|
2007-10-11 |
2009-04-15 |
Bayer Schering Pharma AG |
Benzocycloheptanderivate als selektiv wirksame Estrogene
|
|
WO2009101634A2
(en)
|
2008-02-13 |
2009-08-20 |
Lupin Limited |
A novel process for the preparation of eszopiclone
|
|
DE102010030538A1
(de)
|
2010-06-25 |
2011-12-29 |
Bayer Schering Pharma Aktiengesellschaft |
6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
|
|
GB2483736B
(en)
|
2010-09-16 |
2012-08-29 |
Aragon Pharmaceuticals Inc |
Estrogen receptor modulators and uses thereof
|
|
US20120130129A1
(en)
|
2010-11-16 |
2012-05-24 |
Baylor University |
Efficient Method for Preparing Functionalized Benzosuberenes
|
|
CA2819299A1
(en)
|
2010-12-24 |
2012-06-28 |
Merck Sharp & Dohme B.V. |
N-substituted azetidine derivatives
|
|
DE102011087987A1
(de)
|
2011-12-08 |
2013-06-13 |
Bayer Intellectual Property Gmbh |
6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
|
|
CN102584687A
(zh)
|
2011-12-30 |
2012-07-18 |
北京赛林泰医药技术有限公司 |
作为选择性雌激素受体调节剂的乙烯衍生物
|
|
KR20150039705A
(ko)
|
2011-12-30 |
2015-04-13 |
켄타우루스 바이오파마 컴퍼니 리미티드 |
신규 아릴알켄 유도체 및 이의 선택성 에스트로겐 수용체 조절제에 있어서의 응용
|
|
EP4772247A2
(en)
|
2013-08-14 |
2026-07-08 |
Novartis AG |
Combination therapy comprising ribociclib and fulvestrant for the treatment of cancer
|
|
WO2015028409A1
(de)
|
2013-08-27 |
2015-03-05 |
Bayer Pharma Aktiengesellschaft |
6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
|
|
MX2016007282A
(es)
|
2013-12-06 |
2016-09-07 |
Hoffmann La Roche |
Modulador del receptor de estrogenos para el tratamiento de cancer de mama positivo al receptor de estrogenos localmente avanzado o metastasico.
|
|
EP3200772B1
(en)
|
2014-10-03 |
2022-08-03 |
Novartis AG |
Pharmaceutical compositions comprising alpelisib
|
|
WO2016097071A1
(en)
|
2014-12-18 |
2016-06-23 |
F. Hoffmann-La Roche Ag |
Estrogen receptor modulators and uses thereof
|
|
TWI784255B
(zh)
|
2014-12-18 |
2022-11-21 |
瑞士商赫孚孟拉羅股份公司 |
四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
|
|
MX384605B
(es)
|
2015-04-29 |
2025-03-14 |
Radius Pharmaceuticals Inc |
Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno.
|
|
US10144728B2
(en)
*
|
2015-10-06 |
2018-12-04 |
Dow Agrosciences Llc |
Alkylation of picolinamides with substituted chloroacylals utilizing a crown ether catalyst
|
|
CN106924210A
(zh)
|
2015-12-29 |
2017-07-07 |
北京新领先医药科技发展有限公司 |
一种含有帕布昔利布的胶囊剂及其制备方法
|
|
SG11201806829TA
(en)
|
2016-02-15 |
2018-09-27 |
Sanofi Sa |
6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators
|
|
EP3541809B1
(en)
|
2016-11-17 |
2025-06-25 |
Sanofi |
Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
|
|
EP3434272A1
(en)
|
2017-07-25 |
2019-01-30 |
Sanofi |
Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
|
|
WO2019106604A1
(en)
*
|
2017-12-01 |
2019-06-06 |
Novartis Ag |
Pharmaceutical combination comprising lsz102 and alpelisib
|
|
CN109896991B
(zh)
|
2017-12-08 |
2020-11-20 |
苏州远智医药科技有限公司 |
一种δ阿片受体拮抗剂及其用途和药物组合物
|
|
TWI702219B
(zh)
*
|
2018-07-12 |
2020-08-21 |
美商美國禮來大藥廠 |
選擇性雌激素受體降解劑
|
|
DK3847157T3
(da)
|
2018-09-07 |
2022-08-08 |
Sanofi Sa |
Fremgangsmåde til fremstilling af methyl-[6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylat] og salt deraf
|
|
EP3880202A2
(en)
|
2018-11-16 |
2021-09-22 |
ArQule, Inc. |
Pharmaceutical combination for treatment of cancer
|
|
WO2020112765A1
(en)
|
2018-11-30 |
2020-06-04 |
Radius Pharmaceuticals, Inc. |
Elacestrant in combination with abemaciclib in women with breast cancer
|
|
SG11202111979SA
(en)
|
2019-05-09 |
2021-11-29 |
Sanofi Sa |
6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid for use in metastatic or advanced breast cancer patients
|
|
WO2021063967A1
(en)
|
2019-10-01 |
2021-04-08 |
Sanofi |
Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
|
|
CA3160897A1
(en)
|
2019-12-09 |
2021-06-17 |
Sanofi |
Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative
|
|
EP4069225A4
(en)
*
|
2019-12-20 |
2023-12-27 |
Recurium IP Holdings, LLC |
COMBINATIONS
|
|
MX2022010425A
(es)
*
|
2020-03-06 |
2022-09-07 |
Olema Pharmaceuticals Inc |
Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos.
|
|
IL302152B1
(en)
|
2020-10-19 |
2026-07-01 |
Sanofi Sa |
6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES
|
|
IL302153B1
(en)
|
2020-10-19 |
2026-07-01 |
Sanofi Sa |
6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES
|
|
WO2022106711A1
(en)
|
2020-11-23 |
2022-05-27 |
Sanofi |
Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
|
|
TW202304424A
(zh)
|
2021-04-12 |
2023-02-01 |
法商賽諾菲公司 |
包含依維莫司和安森司群的組合
|
|
TW202304425A
(zh)
|
2021-04-12 |
2023-02-01 |
法商賽諾菲公司 |
包含瑞博西尼和安森司群（ａｍｃｅｎｅｓｔｒａｎｔ）的組合
|